Atara Biotherapeutics Return on Equity

Atara Biotherapeutics (ATRA) currently reports a ROE of 25.37%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Atara Biotherapeutics's ROE history and peer comparisons.

Atara Biotherapeutics's ROE of 25.37% is lower than the Healthcare sector average of 29.33%. That is roughly 13.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Atara Biotherapeutics's current 25.37% should be judged against Healthcare norms (sector average: 29.33%) and against ATRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 25.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Atara Biotherapeutics, and consider following ATRA for alerts when major investors trade the stock.

Atara Biotherapeutics is classified in the Healthcare sector. On ROE, it currently shows 25.37% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATRA with unrelated industries.